Seeking Alpha

Valeant Pharmaceuticals (VRX -0.7%) gave back early gains to finish lower after the drug-maker...

Valeant Pharmaceuticals (VRX -0.7%) gave back early gains to finish lower after the drug-maker reported Q3 result that beat bottom line estimates on a 47% increase in quarterly revenue. Same-store organic growth rose by 14%, but net profit fell on higher costs. Looking forward, the company narrows Q4 earnings projections to $1.30 to $1.35. The Street is at $1.30. For FY12, the company guides its EPS to around $4.60 to $4.65, in-line with expectations of $4.63.

Check out Seeking Alpha’s new Earnings Center »

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs